Understanding Gleason Scores in Prostate Cancer Diagnosis
Author: Ian C. Langtree - Writer/Editor for Disabled World (DW)
Published: 26 Jan 2025 - Updated: 1 Jul 2026
Publication Type: Informative
Contents: Synopsis - Definition - Introduction - Main - Insights, Updates - Related Publications
Synopsis: This information explains the Gleason scoring system, the method pathologists use to grade prostate cancer by examining the pattern of cancer cells in biopsy tissue under a microscope. It is authoritative because it lays out the clinical grading process in plain language, pairing each score from 6 to 10 with its level of aggressiveness, its risk of spreading, and the treatment approaches physicians typically consider, from active surveillance through to combined surgery, radiation, and chemotherapy. The guide is genuinely useful for men facing a prostate cancer diagnosis, including older adults and those managing other conditions, because it clarifies why a 3+4 differs from a 4+3 despite both totaling 7, and how the Gleason score fits alongside PI-RADS imaging and PSA testing within the wider diagnostic picture, giving patients and their families the grounding to take part in treatment decisions with confidence.
At a Glance
- 1 - The score combines a primary grade for the most common cell pattern with a secondary grade for the next most common. Each grade runs from 1 to 5.
- 2 - PI-RADS is a pre-diagnosis MRI system that flags suspicious areas, while Gleason grading happens after biopsy. The workflow moves from PI-RADS to biopsy to Gleason scoring.
- 3 - A Gleason 6 (3+3) describes well-differentiated cells that grow slowly and often warrant only active surveillance, whereas a Gleason 10 (5+5) marks undifferentiated cancer needing aggressive multimodal treatment. The score alone does not decide care, since stage, PSA levels, and overall health also matter.
- Topic Definition: Gleason Score
A Gleason score is a grading measure that describes how aggressive prostate cancer is likely to be, based on how the cancer cells look under a microscope compared with healthy prostate tissue. A pathologist assigns two grades, each from 1 to 5, one for the most common cell pattern in the sample and one for the second most common, then adds them together to produce a total that generally ranges from 6 to 10. A lower total points to slow-growing, less threatening disease, while a higher total signals cancer that is more likely to grow quickly and spread to nearby tissue or beyond. Because it predicts behavior rather than simply confirming the presence of cancer, the Gleason score sits at the center of treatment planning, working together with the cancer's stage, PSA blood levels, and the patient's general health to shape decisions that can range from careful monitoring to surgery, radiation, or combined therapy.
Introduction
Prostate cancer is one of the most common cancers among men, and its diagnosis often involves a Gleason score, which plays a crucial role in determining the aggressiveness of the cancer and guiding treatment decisions. The Gleason score is derived from the Gleason grading system, a method used by pathologists to evaluate the pattern of cancer cells in prostate tissue samples. Understanding this score can help patients and healthcare providers make informed decisions about the course of treatment.
Main Content
What is the Gleason Score?
The Gleason score is a numerical value used to describe the aggressiveness of prostate cancer based on the pattern and appearance of cancerous cells when viewed under a microscope. The score is made up of two components:
- Primary grade: The most common pattern seen in the biopsy sample.
- Secondary grade: The second most common pattern observed.
Each grade is assigned a number between 1 and 5, with 1 representing the least aggressive cells and 5 representing the most aggressive. The two grades are then added together to form the Gleason score. For example, if the primary grade is 3 and the secondary grade is 4, the Gleason score would be 7 (3+4).
Gleason Score and Cancer Aggressiveness
The Gleason score provides information about how likely the cancer is to spread (metastasize). Higher scores indicate more aggressive cancers, which are more likely to grow and spread quickly. On the other hand, lower scores generally suggest that the cancer is less aggressive and may grow more slowly.
Breakdown of Gleason Scores
| Gleason Score | Description | Aggressiveness | Risk of Metastasis | Treatment Considerations |
|---|---|---|---|---|
| 6 (3+3) | Well-differentiated cancer (low grade) | Low | Low | Often treated with active surveillance or surgery. |
| 7 (3+4) or (4+3) | Moderately differentiated cancer | Moderate | Intermediate | Options may include surgery, radiation, or active surveillance. |
| 8 (4+4) | Poorly differentiated cancer | High | High | Aggressive treatment such as surgery, radiation, or hormone therapy. |
| 9 (4+5) or (5+4) | Very poorly differentiated cancer | Very High | Very High | Intensive treatment, often involving a combination of surgery, radiation, and chemotherapy. |
| 10 (5+5) | Undifferentiated cancer (high grade) | Very High | Very High | Requires aggressive multimodal treatment, possibly with clinical trials. |
Detailed Explanation of Gleason Score Ranges
Gleason Score 6 (3+3) - Low Risk:
The cancer cells in this category resemble normal cells and grow slowly. This is considered a low-grade cancer and is less likely to spread. Treatment options may include active surveillance or surgery, depending on the patient's overall health and preferences.
Dropping the Cancer Label May Cut Prostate Deaths: A UCLA-led model finds relabeling the lowest-risk prostate cancer could cut overtreatment and prevent nearly 2,400 deaths a year through more screening.
Gleason Score 7 (3+4 or 4+3) - Intermediate Risk:
This score indicates moderately differentiated cancer, where cells look more abnormal and may grow more quickly than low-grade cancers. Gleason 7 cancers are considered intermediate in terms of aggressiveness and risk of metastasis. Treatment often includes surgery, radiation, or active surveillance, based on other factors such as age and overall health.
Gleason Score 8 (4+4) - High Risk:
At this level, the cancer is more likely to spread to surrounding tissues and organs. Gleason 8 cancers require aggressive treatment, such as surgery or radiation therapy, and may be accompanied by hormone therapy. The prognosis depends on other factors, including the patient's general health.
Gleason Score 9 (4+5 or 5+4) - Very High Risk:
This represents highly aggressive cancer that is likely to grow and spread quickly. Treatment typically involves a combination of surgery, radiation, and possibly chemotherapy or hormone therapy. The prognosis depends on the extent of spread and response to treatment.
Gleason Score 10 (5+5) - Extremely High Risk:
Gleason 10 cancers are the most aggressive form of prostate cancer. The cancer cells are poorly differentiated, meaning they bear little resemblance to normal prostate tissue. The likelihood of metastasis is very high, and treatment is aggressive, often combining surgery, radiation, chemotherapy, and experimental therapies. The outlook can vary, depending on how well the cancer responds to treatment.
Difference Between Gleason Score and PI-RADS
The Gleason Score and the Prostate Imaging Reporting and Data System (PI-RADS) are both used in the context of prostate cancer, but they serve different purposes and assess different aspects of the disease. The Gleason score is a post-diagnosis grading system that evaluates cancer aggressiveness, while PI-RADS is a pre-diagnosis imaging-based scoring system that helps assess the likelihood of cancer.
PI-RADS is a standardized scoring system used to assess the likelihood of prostate cancer being present based on prostate MRI images. It helps radiologists and clinicians identify areas within the prostate that may require biopsy. The PI-RADS system grades prostate lesions on a scale of 1 to 5 based on MRI findings.
The Gleason score is used to grade the aggressiveness of prostate cancer based on how the cancer cells look under a microscope. It helps in determining how likely the cancer is to grow and spread.
Workflow: PI-RADS → Biopsy → Gleason Scoring.
Additional Considerations
While the Gleason score is an important factor in understanding prostate cancer's aggressiveness, it is not the only factor considered in determining treatment. Other elements, such as the stage of the cancer (how far it has spread), PSA (Prostate-Specific Antigen) levels, and patient health, all play crucial roles in creating a comprehensive treatment plan.
The Gleason score is just one piece of the puzzle but provides invaluable information that helps physicians and patients make decisions about how to best manage the disease.
Conclusion
In summary, the Gleason score is a key factor in understanding the aggressiveness of prostate cancer. By providing a detailed look at how the cancer cells appear under a microscope, it helps guide treatment decisions and can help predict the cancer's behavior. While lower Gleason scores (6) indicate slow-growing cancer that may not require aggressive treatment, higher scores (7-10) suggest more aggressive cancers that require more intensive management. It's important for patients to discuss their Gleason score with their healthcare team to fully understand the implications and decide on the best course of action for their care.
Insights, Analysis, and Developments
Editorial Note: The lasting value of the Gleason system lies in how it turns something as intangible as a cell's microscopic appearance into a practical roadmap for treatment. A man handed a number between 6 and 10 is really being told how much time he has to think, how urgently his medical team needs to act, and which options genuinely belong on the table. That translation from tissue slide to treatment plan is why the system has held its place in oncology for decades, and why a frank conversation about one's own score with a trusted physician remains one of the most useful steps a patient can take after diagnosis.
Author Credentials: Ian is the founder and Editor-in-Chief of Disabled World, a leading resource for news and information on disability issues. With a global perspective shaped by years of travel and lived experience, Ian is a committed proponent of the Social Model of Disability-a transformative framework developed by disabled activists in the 1970s that emphasizes dismantling societal barriers rather than focusing solely on individual impairments. His work reflects a deep commitment to disability rights, accessibility, and social inclusion. To learn more about Ian's background, expertise, and accomplishments, visit his full biography.